Minerva Neurosciences, Inc. — FY2019 Form 10-K
Reporting period: Fiscal year ended December 31, 2019; the filing also presents fourth-quarter results. The company is a clinical-stage CNS biopharmaceutical developer with no approved products and no product-sale revenue. Its principal programs are roluperidone for schizophrenia, seltorexant for insomnia and adjunctive treatment of major depressive disorder (MDD), and MIN-301 for Parkinson’s disease.
Financial and operating results
| Metric | FY2019 | FY2018 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $58.1 million | $34.9 million |
| General and administrative expense | $17.7 million | $16.8 million |
| Total operating expenses / operating loss | $75.9 million / $(75.9) million | $51.7 million / $(51.7) million |
| Net loss | $(72.2) million | $(50.2) million |
| Net loss per share, basic and diluted | $(1.85) | $(1.29) |
| Net cash used in operating activities | $43.4 million | $41.9 million |
Margins are not meaningful for this pre-revenue company. R&D expense rose $23.2 million, primarily reflecting a $19.0 million MIN-117 asset impairment and higher roluperidone and MIN-117 trial costs. The impairment followed MIN-117’s failure to meet its primary and key secondary MDD endpoints. G&A increased about $0.9 million. A $2.3 million income-tax benefit partially reduced the 2019 net loss.
At year-end, cash and cash equivalents were $21.4 million, marketable securities $24.4 million, and restricted cash $0.1 million, totaling $46.0 million. Current assets were $47.1 million and current liabilities $6.6 million. Total liabilities were $49.7 million, including $41.2 million of deferred revenue and $1.8 million of deferred taxes; the company reported no outstanding debt. Its former term loan was fully repaid in 2018. Stockholders’ equity fell to $27.8 million from $90.3 million, and accumulated deficit reached $286.7 million.
Investing activities provided $14.1 million, largely reflecting net marketable-security maturities; financing activities provided $0.5 million from option exercises. Cash, cash equivalents and restricted cash declined $28.8 million. Management said available cash, cash equivalents, restricted cash and securities should fund commitments for at least 12 months after issuance of the financial statements, while also stating that additional capital will be needed to fund operations and later-stage development.
Material developments, outlook and risks
- Roluperidone: The pivotal Phase 3 trial for schizophrenia negative symptoms completed enrollment with 515 patients. Management expected top-line results from the 12-week blinded portion in Q2 2020. A commercial supply agreement with Catalent was signed; manufacturing scale-up and validation remained in progress.
- MIN-117: The Phase 2b MDD trial failed its primary and key secondary endpoints. The company said it had no plans for further MDD development and recorded a full $19.0 million impairment of the related in-process R&D asset.
- Seltorexant: Phase 2b trials reported positive insomnia results and a signal in adjunctive MDD. In the MDD2001 trial, the 20 mg dose’s week-six MADRS difference from placebo was 3.1 points, with p=0.083 under a prespecified 0.1 significance threshold. These findings are not proof of Phase 3 success.
- Janssen dispute: Minerva disagreed that contractual “Decision Point 4” had been reached, which would trigger cost-sharing. Janssen invoiced $3.4 million in January 2020 for Minerva’s claimed 40% share of 2019 Phase 3 costs; Minerva had not accrued the amount. Janssen estimated about $100 million of Phase 3 costs in 2020. If the milestone is found to have been reached, Minerva could face substantial costs; resolution and potential financial impact were uncertain.
- MIN-301: Development remained preclinical, with further studies planned before an IND/IMPD filing and a Phase 1 study.
- Other risks: Clinical efficacy, safety, regulatory approval, trial timing, manufacturing, commercialization, reimbursement and financing remain uncertain. The filing notes a 2019 cyberattack on an external contractor disrupted recruitment in the roluperidone Phase 3 trial. Minerva had 13 full-time employees and no manufacturing facilities or product-liability insurance.
The auditor issued an unqualified opinion on the financial statements and internal controls, while including an explanatory paragraph concerning the Janssen dispute. Management assessed disclosure controls and internal control over financial reporting as effective at December 31, 2019.
Investor verification priorities
- Check the outcome and regulatory implications of the roluperidone Phase 3 trial, including safety, endpoints, and manufacturing readiness.
- Track resolution of the Janssen Decision Point 4 dispute, the $3.4 million invoice, any cost-sharing obligations, and the potential 2020 development-cost exposure.
- Assess whether the seltorexant Phase 2 signals are replicated in later-stage studies and clarify the parties’ development and control rights.
- Monitor cash burn, financing needs and runway against trial plans; the stated 12-month liquidity expectation depends on assumptions and excludes uncertain future obligations.
- Confirm the implications of MIN-117’s discontinuation, the impairment, and any remaining development or licensing obligations.